Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals, and to pharmaceutical compositions useful therefor comprising said analogues.

Abstract: Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo.

Abstract: The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.

Abstract: Biomimetic tendon-reinforced” (BTR) composite structures feature improved properties including a very high strength-to-weight ratio. The basic structure includes plurality of parallel, spaced-apart stuffer members, each with an upper end and a lower end, and a plurality of fiber elements, each having one point connected to the upper end of a stuffer member and another point connected to the lower end of a stuffer member such that the elements form criss-crossing joints between the stuffer members. The stuffer members and fiber elements may optionally be embedded in a matrix material such as an epoxy resin. The fiber elements are preferably carbon fibers, though other materials, including natural or synthetic fibers or metal wires may be used. The stuffer members may be rods, tubes, or spheres, and may be constructed of metal, ceramic or plastic. The stuffer members are preferably spaced apart at equal distances. If the members are tubes, the fiber elements may be dressed through the tubes.

Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.

Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.

Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R1-A2-A3-A4-A5-R2 (I) or a pharmaceutically acceptable salt thereof, wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.

Abstract: The laser medical device includes a Nd:YAlO.sub.3 laser crystal; a pumping system which illuminates the laser crystal with light irradiated from a pumping light source and achieves population inversion of Nd.sup.3+ ion in the laser crystal; and a resonant cavity for resonating light emitted from the Nd.sup.3+ ion to output a laser light having a predetermined wavelength, wherein the wavelength of the laser light falls within the transparent range of quartz optical fibers. The laser medical device may also include a quartz optical fiber for transmitting the laser light; an optical fiber injector for focusing the laser light output by the resonant cavity on one end of the optical fiber; and an optical fiber pen which is coupled to another end of the optical fiber for aiming the laser light transmitted through the optical fiber at a desired location of a subject. These devices use Nd:YAlO.sub.3 crystal as an active laser material and output laser light having a wavelength, such as 1341.4 nm and 1079.